¹PG, ^2,3Assistant Professor, ⁴Professor & HOD, Department of DVL, Gandhi Medical College, Secunderabad, Telangana, INDIA.

Email: reachdoctor@gmail.com

REFERENCES

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9 : 136 – 139.
2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undi-agnosed psoriasis in US adults: Results from NHANES 2003-2004. J AmAcad Dermatol 2009; 60 : 218 – 224
3. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol2012; 51 : 389 – 398.
4. Benham H, Norris P, Goodall J et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 2013; 15 : R136.
5. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN- gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoria-sis and correlation with disease severity. Mediators Inflamm 2005; 2005 :273 – 279.
6. Coimbra S, Oliveira H, Reis F et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor- a levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 2010; 163 : 1282 –1290.
7. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009; 54 : 99 – 105.
8. 8 )Lowes MA, Su arez-Fari ~ nas M, Krueger JG. Immunology of Psoriasis.Annu Rev Immunol 2014; 32 : 227 – 255.
9. Sterry W, Barker J, Boehncke W-H et al. Biological therapies in the sys-temic management of psoriasis International Consensus Conference. Br J Dermatol 2004; 151 (Suppl 69): 3 – 17.
10. Reich K, Hartl C, Gambichler T, Zschocke I. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). J Dtsch Dermatol Ges J Ger Soc Der-matol JDDG 2016; 14 : 50 – 58.
11. Nast A, Boehncke WH, Mrowietz U et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2012;304 : 87 – 113.
12. Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75 : 736 – 739.
13. Richter L, Vujic I, Sesti A et al. Etanercept, adalimumab, and ustek-inumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 2017; 15 : 309 – 317.
14. Pathirana D, Ormerod A, Saiag P et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 : 1 – 70.
15. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustek- inumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, pla- cebo-controlled trial (PHOENIX 2). Lancet 2008; 371 : 1675 – 1684.
16. European Medicines Agency. URL http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp. (last accessed: 30 April 2017).
17. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155 : 308 –315.
18. Schafer PH, Chen P, Fang L, Wang A, Chopra R. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulat-ing levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial(PALACE 1). J Immunol Res 2015; 2015 : Article ID 906349.
19. Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast,an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173 : 1387 – 1399.
20. Gottlieb AB, Matheson RT, Menter A et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol JDD 2013; 12 : 888 – 897.
21. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized con- trolled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152 : 1304 – 1312.
22. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodi-esterase 4 (PDE4) inhibitor, in patients with moderate to severe plaquepsoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM]1). J Am Acad Dermatol 2015; 73 : 37 – 49.
23. Kavanaugh A, Mease PJ, Gomez-Reino JJ et al. Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. J Rheumatol 2015; 42 : 479 – 488.
24. Mayba JN, Gooderham MJ. Real-World Experience With Apremilast in Treating Psoriasis. J Cutan Med Surg 2017; 21 : 145 – 151.
25. Warren RB, Smith CH, Yiu ZZN et al. Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol 2015; 135 :2632 – 2640.